Tissue Regenix Group plc (AIM:TRX)

Market Cap	5.16M -86.6%
Revenue (ttm)	20.26M +4.3%
Net Income	-997.04K
EPS	-0.01
Shares Out	71.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,223
Average Volume	1,145,991
Open	7.25
Previous Close	7.25
Day's Range	7.00 - 7.50
52-Week Range	4.77 - 66.00
Beta	0.39
RSI	12.03
Earnings Date	Dec 11, 2025

About Tissue Regenix Group

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a technology that natural bone filler solution for osteoinduct...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 92
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: TRX

Financial Performance

In 2024, Tissue Regenix Group's revenue was $28.65 million, an increase of 8.85% compared to the previous year's $26.32 million. Losses were -$713,000, -58.38% less than in 2023.

Financial numbers in USD